NT 10-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

DEF 14A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

NT 10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International Conference on Frailty and Sarcopenia Research (ICFSR) held March 12-14, 2025, in Toulouse, France. The presentation included positive Phase 2a clinica

Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

Fully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss and frailty Study builds on positive results achieved in earlier Phase 2a trial TNF-alpha inhibitor market estimated at $40+ billion with no FDA-approved oral treatments TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for chronic inflamma

Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including Wegovy® or Ozempic® Lean body mass accounts for up to 40% of weight loss from GLP-1 treatments Potential entry into high growth GLP-1 market of nearly $50 billion in 2024, projected value of $100 billion by 2029 TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple indications. The Company successfully completed an FDA-reco

Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning to identify targeted patient pool Potential entry into high growth GLP-1 market valued at nearly $50 billion in 2024 and projected to surpass $100 billion by 2029 TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhib

Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to begin enrollment First oral TNF-α inhibitor, if approved, would offer potential patient benefit in an approximate $40 billion TNF inhibitor market TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that significant positive topline results from a Phase 2a study of its lead drug candidate MYMD-1® (isomyosamine) was presented at a prestigious international congress of global experts in

Prevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade TNF Pharmaceuticals fully funded for clinical trials for next two years TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has secured a strategic equity investment, priced at a 20% premium to a 30-trading days volume weighted average price (VWAP), from Prevail Partners, LLC, a U.S. investment fund fo

MYMD-1® development to continue through fully funded mid-stage clinical trials Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with statistical significance MYMD-1 shown to inhibit excessive activity of TNF-alpha to regulate the immuno-metabolic system Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto's thyroiditis TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory con

SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)